肿瘤相关巨噬细胞参与贝伐单抗耐药机制的研究进展  

Research progress on tumor-associated macrophages involved in the mechanism of bevacizumab resistance

作　　者：胡亚杰 韩天 陆滔 胡庆华[1] HU Yajie;HAN Tian;LU Tao;HU Qinghua(School of Pharmacy,China Pharmaceutical University,Nanjing 211198,China;WuXi AppTecCo.,Ltd.,Shanghai 200131,China)

机构地区：[1]中国药科大学药学院,江苏南京211198 [2]上海药明康德新药开发有限公司,上海200131

出　　处：《药学研究》2022年第5期322-325,共4页Journal of Pharmaceutical Research

摘　　要：贝伐单抗是获得美国食品药品监督管理局(FDA)批准上市的抗肿瘤血管生成药物,其耐药问题的出现对临床治疗产生了重大影响。因此,阐明其耐药机制、延缓、克服耐药可提高贝伐单抗的临床效果,有效延长肿瘤患者的生存期。在贝伐单抗治疗过程中,巨噬细胞被招募到肿瘤组织或微环境中,并进一步转变为肿瘤相关巨噬细胞(tumor-associated macrophages,TAM),从而驱动肿瘤的发生发展。本文就肿瘤相关巨噬细胞参与贝伐单抗耐药机制的研究现状予以综述,旨在系统性地阐明肿瘤相关巨噬细胞在肿瘤增殖和转移中的作用,为缓解或消除贝伐单抗的耐药提供理论支持。Bevacizumab is an anti-tumor angiogenesis drug approved by the FDA.With the deepening of treatment,the emergence of its drug resistance has a significant impact on clinical treatment.Therefore,clarifying the mechanism of drug resistance,delaying and overcoming drug resistance can improve the clinical efficacy of bevacizumab and effectively prolong the survival period of cancer patients.During the treatment of bevacizumab,macrophages are recruited into tumor tissues and further transformed into tumor-associated macrophages promotes the occurrence and development of tumors.This article reviewed the current research status of tumor-associated macrophages involved in bevacizumab resistance,aiming to systematically clarify the role of tumor-associated macrophages in tumor proliferation,invasion and metastasis,and provided theoretical support for the use of effective means to alleviate or eliminate bevacizumab resistance.

关 键 词：贝伐单抗 肿瘤相关巨噬细胞 耐药机制 肿瘤细胞 

分 类 号：R730.231[医药卫生—肿瘤]